Aramchol
Primary Sclerosing Cholangitis (PSC)
Key Facts
About Galmed Pharmaceuticals
Galmed Pharmaceuticals is dedicated to addressing the significant unmet medical need in chronic liver diseases through its innovative small molecule platform. The company's primary asset, Aramchol, has undergone extensive clinical evaluation in NASH, including a Phase 2b/3 study (ARMOR), and is being repositioned for PSC. Despite clinical setbacks and strategic shifts, Galmed continues to explore the therapeutic potential of its lead compound while managing its financial resources to advance its pipeline.
View full company profileAbout Galmed Pharmaceuticals
Galmed Pharmaceuticals is dedicated to addressing the significant unmet medical need in chronic liver diseases through its innovative small molecule platform. The company's primary asset, Aramchol, has undergone extensive clinical evaluation in NASH, including a Phase 2b/3 study (ARMOR), and is being repositioned for PSC. Despite clinical setbacks and strategic shifts, Galmed continues to explore the therapeutic potential of its lead compound while managing its financial resources to advance its pipeline.
View full company profileTherapeutic Areas
Other Primary Sclerosing Cholangitis (PSC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Bexotegrast (PLN-74809) | Pliant Therapeutics | Phase 2a |